Table 1 Baseline patient characteristics
From: Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
Characteristics | (n = 42) |
|---|---|
Age, years | 61 (40–79) |
Male sex | 31 (73.8%) |
Liver cirrhosis | 31 (73.8%) |
Tumor stage | |
BCLC B | 5 (11.9%) |
BCLC C | 37 (88.1%) |
Etiology | |
HBV | 30 (71.4%) |
HCV | 5 (11.9%) |
Others | 7 (16.7%) |
Extrahepatic spread | |
Lung | 20 (47.6%) |
Lymph node | 11 (26.2%) |
Peritoneum | 8 (19.1%) |
Bone | 5 (11.9%) |
Other | 4 (9.5%) |
Previous treatment for HCC | |
Surgical resection | 21 (50.0%) |
Radiation therapy | 12 (28.6%) |
Transarterial chemoembolization | 35 (83.3%) |
Radiofrequency ablation | 5 (11.9%) |
Transarterial embolization | 1 (2.4%) |
Transarterial radioembolization | 1 (2.4%) |
